Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | G6PD | P11413 | 3/20 | 0.61 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | SHBG | P04278 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1324961 | 1.00 | G6PD (0.61) | G6PDSERPINA6LMNAGPBAR1CYP1A2 | |
| SCHEMBL19330943 | 0.93 | G6PD (0.64) | G6PDSERPINA6LMNAGPBAR1CYP1A2 | |
| SCHEMBL16431616 | 0.93 | G6PD (0.64) | G6PDSERPINA6LMNAGPBAR1CYP1A2 | |
| SCHEMBL598321 | 0.93 | G6PD (0.64) | G6PDSERPINA6LMNAGPBAR1CYP1A2 | |
| SCHEMBL598190 | 0.93 | G6PD (0.64) | G6PDSERPINA6LMNAGPBAR1CYP1A2 | |
| SCHEMBL9436439 | 0.88 | G6PD (0.67) | G6PDSERPINA6LMNAGPBAR1CYP1A2 | |
| SCHEMBL16225749 | 0.88 | G6PD (0.67) | G6PDSERPINA6LMNAGPBAR1CYP1A2 | |
| SCHEMBL1872625 | 0.88 | G6PD (0.67) | G6PDSERPINA6LMNAGPBAR1CYP1A2 | |
| SCHEMBL4934329 | 0.88 | G6PD (0.67) | G6PDSERPINA6LMNAGPBAR1CYP1A2 | |
| SCHEMBL16225853 | 0.88 | G6PD (0.67) | G6PDSERPINA6LMNAGPBAR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2527356-B1 | Process for the Production of 3-Oxo-pregn-4-ene-21,17-carbolactones by the Metal-Free Oxidation of 17-(3-Hydroxypropyl)-3,17-dihydroxyandrostanes | BAYER IP GMBH (DE) | 2018-01-03 | — | — | EP | disclosed |
| EP-2527356-B1 | Process for the Production of 3-Oxo-pregn-4-ene-21,17-carbolactones by the Metal-Free Oxidation of 17-(3-Hydroxypropyl)-3,17-dihydroxyandrostanes | BAYER IP GMBH (DE) | 2018-01-03 | — | — | EP | disclosed |
| EP-1910403-B1 | PROCESS FOR THE PRODUCTION OF 3-OXO-PREGN-4-ENE-21,17-CARBOLACTONES BY THE METAL-FREE OXIDATION OF 17-(3-HYDROXYPROPYL)-3,17-DIHYDROXYANDROSTANES | Bayer Pharma AG (DE) | 2016-04-27 | — | — | EP | disclosed |
| EP-1746101-B2 | Process for the production of Oxo-pregn-4-en-21,17-carbolactonen by metal free oxidation of 17-(3-hydroxypropyl)-3,17-dihydroxyandrostanes | Bayer Pharma AG (DE) | 2014-05-14 | — | — | EP | disclosed |
| EP-2527356-A3 | Process for the Production of 3-Oxo-pregn-4-ene-21,17-carbolactones by the Metal-Free Oxidation of 17-(3-Hydroxypropyl)-3,17-dihydroxyandrostanes | Bayer Pharma Aktiengesellschaft (DE) | 2014-04-09 | — | — | EP | disclosed |
| EP-2527356-A3 | Process for the Production of 3-Oxo-pregn-4-ene-21,17-carbolactones by the Metal-Free Oxidation of 17-(3-Hydroxypropyl)-3,17-dihydroxyandrostanes | Bayer Pharma Aktiengesellschaft (DE) | 2014-04-09 | — | — | EP | disclosed |
| US-8658788-B2 | Process for the production of 3-oxo-pregn-4-ene-21,17-carbolactones by the metal-free oxidation of 17-(3-hydroxypropyl)-3,17-dihydroxyandrostanes | Bayer Pharma AG (DE) | 2014-02-25 | — | — | US | disclosed |
| US-8658788-B2 | Process for the production of 3-oxo-pregn-4-ene-21,17-carbolactones by the metal-free oxidation of 17-(3-hydroxypropyl)-3,17-dihydroxyandrostanes | Bayer Pharma AG (DE) | 2014-02-25 | — | — | US | disclosed |
| US-8658788-B2 | Process for the production of 3-oxo-pregn-4-ene-21,17-carbolactones by the metal-free oxidation of 17-(3-hydroxypropyl)-3,17-dihydroxyandrostanes | Bayer Pharma AG (DE) | 2014-02-25 | — | — | US | disclosed |
| US-RE44734-E1 | Process for the production of 3-oxo-pregn-4-ene-21,17-carbolactones by the metal free oxidation of 17-(3-hydroxypropyl)-3,17-dihydroxyandrostanes | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-01-28 | — | — | US | disclosed |
| US-7319154-B2 | Oxidation of 17 alpha -(3-hydroxypropyl)-6 beta ,7 beta ;15 beta ,16 beta -dimethylene-androstane-3 beta ,5 beta ,17 beta -triol in the presence of a catalytic amounts of a 2,2,6,6-tetramethylpiperidine-N-oxide derivative at a pH of at least 8.0 | BAYER SCHERING PHARMA AG (DE) | 2008-01-15 | — | — | US | disclosed |
| US-20070049747-A1 | Process for the production of 3-oxo-pregn-4-ene-21, 17-carbolactones by the metal-free oxidation of 17-(3-hydroxypropyl)-3,17-dihydroxyandrostanes | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2007-03-01 | — | — | US | disclosed |
| US-20070049747-A1 | Process for the production of 3-oxo-pregn-4-ene-21, 17-carbolactones by the metal-free oxidation of 17-(3-hydroxypropyl)-3,17-dihydroxyandrostanes | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2007-03-01 | — | — | US | disclosed |
| US-20070049747-A1 | Process for the production of 3-oxo-pregn-4-ene-21, 17-carbolactones by the metal-free oxidation of 17-(3-hydroxypropyl)-3,17-dihydroxyandrostanes | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2007-03-01 | — | — | US | disclosed |
| WO-2007009821-A1 | PROCESS FOR THE PRODUCTION OF 3-OXO-PREGN-4-ENE-21,17-CARBOLACTONES BY THE METAL-FREE OXIDATION OF 17-(3-HYDROXYPROPYL)-3,17-DIHYDROXYANDROSTANES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007009821-A1 | PROCESS FOR THE PRODUCTION OF 3-OXO-PREGN-4-ENE-21,17-CARBOLACTONES BY THE METAL-FREE OXIDATION OF 17-(3-HYDROXYPROPYL)-3,17-DIHYDROXYANDROSTANES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-25 | — | — | WO | disclosed |
| US-20070021603-A1 | Process for the production of 3-oxo-pregn-4-ene-21,17-carbolactones by the metal free oxidation of 17-(3-hydroxypropyl)-3,17-dihydroxyandrostanes | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-25 | — | — | US | disclosed |
| US-20070021603-A1 | Process for the production of 3-oxo-pregn-4-ene-21,17-carbolactones by the metal free oxidation of 17-(3-hydroxypropyl)-3,17-dihydroxyandrostanes | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-25 | — | — | US | disclosed |
| US-20070021603-A1 | Process for the production of 3-oxo-pregn-4-ene-21,17-carbolactones by the metal free oxidation of 17-(3-hydroxypropyl)-3,17-dihydroxyandrostanes | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-25 | — | — | US | disclosed |
| EP-1746101-A1 | Process for the production of Oxo-pregn-4-en-21,17-carbolactonen by metal free oxidation of 17-(3-hydroxypropyl)-3,17-dihydroxyandrostanes | Schering Aktiengesellschaft (DE) | 2007-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021603-A1 | Process for the production of 3-oxo-pregn-4-ene-21,17-carbolactones by the metal free oxidation of 17-(3-hydroxypropyl)-3,17-dihydroxyandrostanes | HSD17B7, HSD17B13, HSD17B3 | G6PD 513/4885SERPINA6 531/4885LMNA 2506/4885 |
| US-20070049747-A1 | Process for the production of 3-oxo-pregn-4-ene-21, 17-carbolactones by the metal-free oxidation of 17-(3-hydroxypropyl)-3,17-dihydroxyandrostanes | HSD17B13, HSD17B3, HSD17B7 | G6PD 1113/4885SERPINA6 489/4885LMNA 2712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.